6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one derivatives as protein kinase modulators
Abstract
There are provided 3,5-disubstituted derivatives of 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one compounds of formula (I) or a pharmaceutically acceptable salt thereof as defined in the present specification, which modulate the activity of protein kinases. The compounds are therefore useful in treating diseases caused by dysregulated protein kinase activity. In particular, such diseases to be treated with a compound of formula (I) of the present invention is one caused by and/or associated with disregulated protein kinase activity selected from the group consisting of cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders. The present invention also relates to processes for preparing the compounds of formula (I), combinatorial libraries thereof, pharmaceutical compositions comprising them, and methods of treating diseases utilizing pharmaceutical compositions comprising a compound of formula (I).
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A compound of the formula (I):
wherein:
R 1 is —NR 3 R 4 or —OR 3 ;
R 2 is a hydrogen atom or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, aryl, heteroaryl, aryl C 1 -C 6 alkyl and heteroaryl C 1 -C 6 alkyl;
R 3 and R 4 , the same or different, are each independently hydrogen atom or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, cycloalkyl C 1 -C 6 alkyl, heterocyclyl, heterocyclyl C 1 -C 6 alkyl, aryl, aryl C 1 -C 6 alkyl, heteroaryl and heteroaryl C 1 -C 6 alkyl, or R 3 and R 4 , taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 3 to 7 membered heterocyclyl or heteroaryl ring, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N and NH; or a pharmaceutically acceptable salt thereof, wherein the optionally substituted group of R 2 , R 3 and R 4 is substituted in any of its free positions by 1 to 6 groups, selected from the groups consisting of: halogen, nitro, oxo groups (═O), carboxy, cyano, C 1 -C 6 alkyl, polyfluorinated alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl; amino groups and derivatives thereof; carbonylamino groups and derivatives thereof; hydroxy groups and derivatives thereof; carbonyl groups and derivatives thereof; and sulfurated derivatives, wherein when R 1 is —NR 3 R 4 , only one of R 3 and R 4 are hydrogen and when R 1 is —OR 3 , R 3 is not hydrogen.
2. A compound of formula (I) according to claim 1 wherein R 1 is —NH 2 or NHR 3 and R 3 is a straight or branched C 1 -C 6 alkyl or C 2 -C 6 alkenyl group or it is an optionally substituted aryl or arylalkyl group, wherein the optionally substituted aryl or arlyalkyl of R 3 is substituted in any of its free positions by 1 to 6 groups, selected from the groups consisting of: halogen, nitro, oxo groups (═O), carboxy, cyano, C 1 -C 6 alkyl, polyfluorinated alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl; amino groups and derivatives thereof; carbonylamino groups and derivatives thereof; hydroxy groups and derivatives thereof; carbonyl groups and derivatives thereof; and sulfurated derivatives.
3. A compound of formula (I) according to claim 1 wherein R 2 is hydrogen or an optionally substituted aryl or heteroaryl group, wherein the optionally substituted aryl or heteroaryl of R 2 is substituted in any of its free positions by 1 to 6 groups, selected from the groups consisting of: halogen, nitro, oxo groups (═O), carboxy, cyano, C 1 -C 6 alkyl, polyfluorinated alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl; amino groups and derivatives thereof; carbonylamino groups and derivatives thereof; hydroxy groups and derivatives thereof; carbonyl groups and derivatives thereof; and sulfurated derivatives.
4. A compound of formula (I) according to claim 1 wherein R 2 is a fragment denoted by any of codes A1-A18 and R1 is a fragment denoted by any of codes B1-B32:
Fragment
CODE
Fragment
CODE
A1
A9
A2
A10
A3
A11
A4
A12
A5
A13
A6
A14
A7
H—M
A15
A8
A16
A17
A18
B1
B8
B2
B9
B3
B10
B4
B11
B5
HO—M
B12
B6
H 2 N—M
B13
B7
B14
B15
B24
B16
B25
B17
B26
B18
B27
B19
B28
B20
B29
B21
B30
B22
B31
B23
B32.
5. A process for preparing a compound of the formula (I) or the pharmaceutically acceptable salts thereof, as defined in claim 1 , which process comprises:
a) decarboxylating a compound of formula (II):
b) reacting the resultant compound of formula (III):
with a compound of formula (IV) or a salt thereof:
wherein R 3 is a C 1 -C 6 alkyl group, so as to obtain a compound of formula (I):
wherein R 3 is a C 1 -C 6 alkyl group and R 2 is hydrogen, or a pharmaceutically acceptable salt thereof and, if necessary or desired, performing one or more of the following additional steps:
separating the compound of formula (I) into the single isomers;
converting a compound of formula (I) into a different compound of formula (I) by introduction on the imidazole moiety of a R 2 group as defined in claim 1 but different from hydrogen;
converting a compound of formula (I) into a different compound of formula (I) by replacing the group —OR 3 with a different group R 1 as defined in claim 1 ;
converting a compound of formula (I) into a pharmaceutically acceptable salt or converting a salt into the free compound (I).
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), as defined in claim 1 , and at least one pharmaceutically acceptable carrier and/or diluent.
7. A pharmaceutical composition according to claim 6 further comprising one or more chemotherapeutic agents.
8. A product comprising a compound of formula (I) as defined in claim 1 or a pharmaceutical composition thereof comprising said compound and at least one pharmaceutically acceptable carrier and/or diluent, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.